Candidate genetic modifiers for breast and ovarian cancer risk inBRCA1andBRCA2 mutation carriers.
Cancer Epidemiology Biomarkers and Prevention.
Times cited: 14
Intraperitoneal cisplatin and paclitaxel in ovarian cancer.
New England Journal of Medicine.
Times cited: 1852
Implications of second-look laparotomy in the context of optimally resected stage III ovarian cancer: A non-randomized comparison using an explanatory analysis: A Gynecologic Oncology Group study.
Times cited: 45